Michael Ropacki

Dr. Michael Ropacki is the Chief Medical Officer (CMO) CNS Clinical Development and US Site Head for Oryzon Genomics, a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need. In addition, he serves as the Founder and President of Strategic Global Research and Development (SGR&D) originally based out of San Francisco, that collaborates with sponsors developing and executing Clinical Development Plans to maximize meaningful and productive regulatory interactions, as well as increase probability of technical and regulatory success. Through SGR&D, Dr. Ropacki serves various boards and committees including Scientific Advisory (SABs) and Data Safety Monitoring Boards/Data Monitoring Committees (DSMBs/DMCs), provides guidance on implementation of digital Drug Development Tools (dDDTs: eConsent, biometric wearables, digital biomarkers), patient recruitment and retention, as well as data review and scientific advice.